Bristol-Myers Squibb 3Q 3Q Revenues: $4.8 billion (flat) 3Q Earnings: $949 million (-2%) YTD Revenues: $14.4 billion (+4%) YTD Earnings: $2.6 billion (+1%) Comments: Plavix sales were up 7% to $1.7 billion, but Abilify sales were -7% to $608 million, resulting from changed rebate rates. Baraclude sales were up 19% to $228 million. Sustiva sales were up 9% to $342 million and Reyataz rose 4% to $375 million. Sprycel sales were $144 million (+35%) and Orencia sales were $184 millio...